Department of Urology, Stanford University School of Medicine, Palo Alto, California, USA.
Department of Obstetrics and Gynecology, Stanford University School of Medicine, Palo Alto, California, USA.
Neurourol Urodyn. 2022 Nov;41(8):1983-1992. doi: 10.1002/nau.24936. Epub 2022 May 5.
To provide an overview of the barriers and facilitators to overactive bladder (OAB) therapy initiation and adherence.
A PubMed and Embase literature search was conducted to identify barriers to OAB therapy adherence.
OAB therapy adherence is associated with improvements in urinary symptoms, and quality of life with reductions in annual costs for OAB-related expenditures. However, adherence rates to behavioral therapies are as low as 32% at 1 year, only 15%-40% of treated patients remain on oral medications at 1 year due to several factors (e.g., inadequate efficacy, tolerability, and cost), and 5%-10% of OAB patients progress to advanced therapies. While some common barriers to therapy adherence are often fixed (e.g., costs, lack of efficacy, time, side effects, treatment fatigue), many are modifiable (e.g., lack of knowledge, poor relationships, negative experiences, poor communication with providers). Patient-centered care may help address some modifiable barriers. Emerging data demonstrate that patient-centered care in the form of treatment navigators improves OAB therapy adherence and progression to advanced therapies in the appropriate patient.
There are numerous modifiable barriers to OAB therapy adherence. A patient-centered lens is needed to elicit patient goals, establish realistic treatment expectations, and tailor therapy to improve therapy adherence, optimize outcomes, and reduce healthcare expenditures. Further research is needed to develop and study low-cost, scalable solutions.
概述影响膀胱过度活动症(OAB)治疗起始和依从性的障碍因素和促进因素。
对 PubMed 和 Embase 文献进行检索,以确定影响 OAB 治疗依从性的障碍因素。
OAB 治疗依从性与改善尿症状和生活质量相关,同时降低了与 OAB 相关支出的年度费用。然而,行为疗法的依从率在 1 年内低至 32%,由于多种因素(如疗效不足、耐受性、成本等),仅有 15%-40%接受口服药物治疗的患者在 1 年内仍在接受治疗,由于多种因素(如疗效不足、耐受性、成本等),仅有 15%-40%接受口服药物治疗的患者在 1 年内仍在接受治疗,由于多种因素(如疗效不足、耐受性、成本等),仅有 15%-40%接受口服药物治疗的患者在 1 年内仍在接受治疗。虽然一些常见的治疗依从性障碍因素通常是固定的(如成本、疗效不足、时间、副作用、治疗疲劳),但许多是可改变的(如缺乏知识、不良关系、负面经历、与提供者沟通不畅)。以患者为中心的护理可能有助于解决一些可改变的障碍因素。新出现的数据表明,以治疗导航员为形式的以患者为中心的护理可提高 OAB 治疗依从性,并使适当患者向先进治疗方法进展。
OAB 治疗依从性存在许多可改变的障碍因素。需要以患者为中心的视角来了解患者的目标,建立现实的治疗期望,并调整治疗方法,以提高治疗依从性、优化治疗效果,并降低医疗保健支出。需要进一步研究以开发和研究低成本、可扩展的解决方案。